Open Orphan Restarts Earlier Coronavirus Vaccine Efforts
London-Listed CRO Talking To Chinese Pharma Backers About Project
Open Orphan’s hVIVO unit, owner of Europe's only quarantine clinic with an onsite virology lab, has begun the world’s first commercial coronavirus human challenge study.
You may also be interested in...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.